FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Io­n­is’ an­ti­sense oligonu­cleotide olezarsen is now the first ap­proved treat­ment for fa­mil­ial chy­lomi­crone­mia syn­drome, a rare meta­bol­ic dis­or­der that pre­vents the body from break­ing down …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER